VeroScience


Veroscience is dedicated to understanding and applying nature’s genius to successfully treat human disease and improve the human condition. The company focuses on innovative technologies and therapies, including Circadian Neuroendocrine Resetting Therapy (CNRT) and Photo Immuno-Resetting Therapy for the treatment of cancer, with a mission to develop effective treatments for metabolic diseases, immunological disorders, and other therapeutic areas.

Industries

biotechnology

Nr. of Employees

small (1-50)

VeroScience

Tiverton, Devon, United Kingdom, Europe


Patents

Method for inducing tumor regression

US-12357693-B2

View Details

Method for inducing tumor regression

US-12318451-B2

View Details

Bromocriptine formulations

US-12274698-B2

View Details

Bromocriptine formulations

US-11883399-B2

View Details

Composition and method for treating metabolic disorders

US-11878974-B2

View Details

Bromocriptine formulations

US-11666567-B2

View Details
View All Patents

Products

FDA-approved dopamine D2 receptor agonist (type 2 diabetes)

An FDA-approved therapeutic agent acting as a dopamine D2 receptor agonist indicated for treatment of type 2 diabetes.

Oncology development candidate (pancreatic cancer)

Therapeutic candidate in development for pancreatic cancer within the company's pipeline.

Pediatric type 2 diabetes therapeutic program

Development program addressing pediatric type 2 diabetes patients.


Services

In vivo rodent model studies and metabolic phenotyping to evaluate disease mechanisms and candidate effects.

Planning and conducting clinical studies for therapeutic candidates to support regulatory submissions.

Experimental characterization of drug mechanisms and pharmacological profiling to support development decisions.

Regulatory filing experience and management of U.S. patent assets related to therapeutic products.

Expertise Areas

  • Circadian biology and neuroendocrine modulation
  • Preclinical in vivo models and metabolic phenotyping
  • Clinical trial management for metabolic disease
  • Molecular biology and neuropharmacology
  • Show More (4)

Key Technologies

  • Circadian neuroendocrine resetting therapy
  • Photodynamic therapy for oncology
  • Dopamine D2 receptor agonist pharmacology
  • Rodent lesion models (SCN/dopaminergic)
  • Show More (3)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.